One drug, two views

[Deb]

The chief executives of Biogen Idec Inc. and Elan Corp. have each made numerous comments about the fate of Tysabri, the multiple sclerosis drug the two firms collaborate on, which was pulled from the market in February. But they have publicly offered different perspectives on Tysabri's fate. click here formore information>
www.boston.com/business/globe/articles/2005/06/14/one_drug_two_views/?page=1